Analystreport

Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com